Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension.
Why the study?
Does bromocriptine alter prolactin, catecholamine, and blood pressure responses in men with essential hypertension compared to normotensive controls?
Population
18 men who reached metabolic equilibrium on a constant intake of 100 mEq sodium and 80 mEq potassium.
Comparison
Bromocriptine vs Normotensive controls and baseline control period
Design
Case-control
Follow-up
24 hours
Authors
Discussion
Loading...
Member takes
Implication
Supports dopaminergic dysregulation in essential hypertension; leaves open therapeutic exploration of bromocriptine in randomized trials.
Structured PICO
Does bromocriptine alter prolactin, catecholamine, and blood pressure responses in men with essential hypertension compared to normotensive controls?
P
Population
18 men (9 with sustained essential hypertension and 9 age- and weight-matched normotensive controls) who reached metabolic equilibrium on a constant intake of 100 mEq sodium and 80 mEq potassium.
I
Intervention
Bromocriptine
C
Comparator
Normotensive controls and baseline control period
O
Outcome
Plasma catecholamine, prolactin (PRL), and mean arterial pressure (MAP) responses to upright posture and isometric handgrip exercise, and recumbent circadian PRL and MAP patternssurrogate
Decreased dopaminergic activity in essential hypertension may partly account for aberrant prolactin secretion and elevated blood pressure, as bromocriptine lowered MAP and altered prolactin responses in hypertensive patients.
Cite This Study
Sowers et al. (1982) studied this question.